{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:06:17Z","timestamp":1762459577263,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"am","delay-in-days":297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ypmed.2018.02.013","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T02:39:15Z","timestamp":1518575955000},"page":"100-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A novel metric that quantifies risk stratification for evaluating diagnostic tests: The example of evaluating cervical-cancer screening tests across populations"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2002-0095","authenticated-orcid":false,"given":"Hormuzd A.","family":"Katki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Schiffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2018.02.013_bb0005","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1002\/sim.6195","article-title":"How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through","volume":"33","author":"Baker","year":"2014","journal-title":"Stat. Med."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0010","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ypmed.2018.02.013_bb0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/0272989X0002000410","article-title":"Determining the area under the ROC curve for a binary diagnostic test","volume":"20","author":"Cantor","year":"2000","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2016.101","article-title":"Screening: a risk-based framework to decide who benefits from screening","volume":"13","author":"Castle","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0025","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","article-title":"Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study","volume":"12","author":"Castle","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0030","unstructured":"Dopart PJ, Ji BT, Xue S, et al. Evaluating differences in expert agreement between subgroups to identify where to prioritize use of multiple raters. (Submitted)."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013711","article-title":"Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India","volume":"5","author":"Gravitt","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ypmed.2018.02.013_bb0040","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/1097-0142(1950)3:6<1097::AID-CNCR2820030620>3.0.CO;2-E","article-title":"The Youden index: letters to the editor","volume":"3","author":"Greenhouse","year":"1950","journal-title":"Cancer"},{"key":"10.1016\/j.ypmed.2018.02.013_bb0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"10.1016\/j.ypmed.2018.02.013_bb0050","unstructured":"Katki HA. Novel decision-theoretic and risk-stratification metrics of predictive performance: application to deciding who should undergo genetic testing. (arXiv 2017;arXiv:1711.05686 [stat.ME])."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0055","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":"Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice","volume":"12","author":"Katki","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0060","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/LGT.0b013e318285423c","article-title":"Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines","volume":"17","author":"Katki","year":"2013","journal-title":"Journal of Lower Genital Tract Disease"},{"key":"10.1016\/j.ypmed.2018.02.013_bb0065","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jama.2014.12483","article-title":"Population-based screening for BRCA1 and BRCA2: 2014 Lasker award","volume":"312","author":"King","year":"2014","journal-title":"JAMA"},{"year":"2000","series-title":"Biostatistical Methods: The Assessment of Relative Risks","author":"Lachin","key":"10.1016\/j.ypmed.2018.02.013_bb0070"},{"key":"10.1016\/j.ypmed.2018.02.013_bb0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/AOG.0b013e3182883a34","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"121","author":"Massad","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0080","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s10985-012-9238-0","article-title":"Understanding increments in model performance metrics","volume":"19","author":"Pencina","year":"2013","journal-title":"Lifetime Data Anal."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0085","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/aje\/kwh101","article-title":"Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker","volume":"159","author":"Pepe","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0090","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2018.02.013_bb0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/LGT.0000000000000300","article-title":"Preparing for the next round of ASCCP-sponsored cervical screening and management guidelines","volume":"21","author":"Schiffman","year":"2017","journal-title":"Journal of Lower Genital Tract Disease"},{"key":"10.1016\/j.ypmed.2018.02.013_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju009","article-title":"Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India","volume":"106","author":"Shastri","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv257","article-title":"p16\/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women","volume":"107","author":"Wentzensen","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/2159-8290.CD-12-0196","article-title":"From differences in means between cases and controls to risk stratification: a business plan for biomarker development","volume":"3","author":"Wentzensen","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ypmed.2018.02.013_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ypmed.2018.02.013_bb0125","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/ijc.30012","article-title":"Risk assessment to guide cervical screening strategies in a large Chinese population","volume":"138","author":"Zhao","year":"2016","journal-title":"Int. J. Cancer"}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743518300409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743518300409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:00:40Z","timestamp":1758794440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743518300409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":25,"alternative-id":["S0091743518300409"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2018.02.013","relation":{},"ISSN":["0091-7435"],"issn-type":[{"type":"print","value":"0091-7435"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel metric that quantifies risk stratification for evaluating diagnostic tests: The example of evaluating cervical-cancer screening tests across populations","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2018.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}